Canada-Wide Settlement: Seeking Justice for Opioid Victims
Purdue Pharma, the manufacturer of OxyContin and OxyNEO, has agreed to a monumental $20 million class action settlement in a pivotal legal development. This groundbreaking agreement, which has received judicial approval in Ontario, Quebec, Nova Scotia, and Saskatchewan, represents a significant stride toward accountability in pharmaceutical litigation.
The Opioid Emergency in Canada
Canada is grappling with a profound opioid crisis, and OxyContin has significantly exacerbated this public health emergency. According to data from the Government of Canada, opioid-related overdoses claimed the lives of over 17,000 individuals between January 2016 and September 2021 alone. There is an urgent need for intervention and continued accountability within the pharmaceutical industry.
OxyContin, a potent opioid pain reliever, gained widespread popularity in Canada following its introduction in the 1990s. Marketed as a revolutionary solution for chronic pain management, the drug’s high potency and addictive properties …